Ebos Group

EBOS Group is a provider of medical and healthcare products to the human and animal markets. Co. operates in two business segments, being Healthcare, which incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare, wholesale activities, and logistics; as well as Animal Care, which incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. Co.'s operations are primarily in New Zealand and Australia.
  • TickerEBO
  • ISINNZEBOE0001S6
  • ExchangeNZX
  • SectorHealth Care Equipment & Services
  • CountryNew Zealand

EBOS Group: 1 director maiden bought

A director at EBOS Group maiden bought 2,000 shares at 23.000NZD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank supersector are two recent developments which have dampened our overall outlook... see charts below. • Tes...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Global equities nearing potential resistance Helped by support from global central banks and improving trade headlines, critical support levels have held for major global indexes and therefore our outlook remains constructive. At the same time, just because these indexes are not breaking down does not mean they are headed higher. Rather, we believe global equities remain in a state of purgatory and consolidation is likely to continue as several major indexes approach logical resistance... see charts below and page 2. With global equity markets generally moving sideways, we want to stick with ...

Brian Han

Morningstar | Ebos Takes Care of Debt After Acquisition Streak

We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our intrinsic assessment, is a sensible capital management initiative. Since fiscal 2014, Ebos has out...

Brian Han

Morningstar | Ebos Takes Care of Debt After Acquisition Streak

We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our intrinsic assessment, is a sensible capital management initiative. Since fiscal 2014, Ebos has out...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank supersector are two recent developments which have dampened our overall outlook... see charts below. • Tes...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Global equities nearing potential resistance Helped by support from global central banks and improving trade headlines, critical support levels have held for major global indexes and therefore our outlook remains constructive. At the same time, just because these indexes are not breaking down does not mean they are headed higher. Rather, we believe global equities remain in a state of purgatory and consolidation is likely to continue as several major indexes approach logical resistance... see charts below and page 2. With global equity markets generally moving sideways, we want to stick with ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

EBOS Group: 1 director maiden bought

A director at EBOS Group maiden bought 2,000 shares at 23.000NZD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Brian Han

Morningstar | Ebos Takes Care of Debt After Acquisition Streak

We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our intrinsic assessment, is a sensible capital management initiative. Since fiscal 2014, Ebos has out...

Brian Han

Morningstar | Ebos Takes Care of Debt After Acquisition Streak

We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our intrinsic assessment, is a sensible capital management initiative. Since fiscal 2014, Ebos has out...

Brian Han

Morningstar | Benefits of Ebos' Recent Diversification Efforts Materialising

Ebos operates a conglomerate business offering a range of products and services targeting the healthcare and animal-care markets in both Australia and New Zealand. Ebos has grown primarily via acquisitions during the past 13 years. Its transformational Symbion acquisition in 2013 propelled Ebos to the second-largest and most diversified pharmaceutical wholesaler and the largest hospital distributor in the Australian market. Ebos Group's narrow economic moat rating is predicated on the efficient scale it enjoys in the Australian pharmaceutical wholesaler market. We believe Symbion provides an a...

Brian Han

Morningstar | Benefits of Ebos' Recent Diversification Efforts Materialising

Ebos operates a conglomerate business offering a range of products and services targeting the healthcare and animal-care markets in both Australia and New Zealand. Ebos has grown primarily via acquisitions during the past 13 years. Its transformational Symbion acquisition in 2013 propelled Ebos to the second-largest and most diversified pharmaceutical wholesaler and the largest hospital distributor in the Australian market. Ebos Group's narrow economic moat rating is predicated on the efficient scale it enjoys in the Australian pharmaceutical wholesaler market. We believe Symbion provides an a...

Brian Han

Ebos Takes Care of Debt After Acquisition Streak

We maintain our AUD 20.00 (NZD 21.00) fair value estimate for Ebos, following the group's fully underwritten NZD 150 million share placement. We calculate the issue to be merely 2% EPS-dilutive on a pro-forma basis, with the 5% increase in the share base partly offset by lower forecast interest charge from the reduced debt. Shares in Ebos were trading broadly in line with our fair value estimate before the capital raising announcement. Issue of the new shares at NZD 19.70 each, just 6% below our...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch